Cargando…

Fructoholism in adults: The importance of personalised care in metabolic dysfunction-associated fatty liver disease

Detalles Bibliográficos
Autores principales:	Salavrakos, Mélissa, de Timary, Philippe, Ruiz Moreno, Alejandra, Thissen, Jean-Paul, Lanthier, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666557/ https://www.ncbi.nlm.nih.gov/pubmed/34917913 http://dx.doi.org/10.1016/j.jhepr.2021.100396

Ejemplares similares

Childhood Fructoholism and Fructoholic Liver Disease
por: Ribeiro, Andreia, et al.
Publicado: (2018)

Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
por: Lanthier, Nicolas, et al.
Publicado: (2022)

A Cross-sectional Real-life Study of the Prevalence, Severity, and Determinants of Metabolic Dysfunction-associated Fatty Liver Disease in Type 2 Diabetes Patients
por: Binet, Quentin, et al.
Publicado: (2023)

Promoting predictive, preventive and personalised medicine: European event of global importance
por: Golubnitschaja, Olga, et al.
Publicado: (2011)

Importance of Variables in Nonalcoholic Fatty Liver Disease Patients
por: Garg, Vivek Kumar, et al.
Publicado: (2018)

Fetuin-A in Activated Liver Macrophages Is a Key Feature of Non-Alcoholic Steatohepatitis
por: Etienne, Quentin, et al.
Publicado: (2022)

Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19
por: Targher, G., et al.
Publicado: (2020)

Psychological distress among hospital caregivers during and after the first wave of COVID-19: Individual factors involved in the severity of symptoms expression
por: Mennicken, Benoit, et al.
Publicado: (2022)

Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
por: Han, A Lum
Publicado: (2022)

A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease
por: Hammoutene, Adel, et al.
Publicado: (2023)

Metabolic Phenotypes: Drivers of Health Outcomes in Fatty Liver Diseases
por: Charatcharoenwitthaya, Phunchai
Publicado: (2023)

Labour analgesia in cardiac parturients: A personalised approach!
por: Choudhary, Nitin, et al.
Publicado: (2020)

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
por: Takamura, Saori, et al.
Publicado: (2022)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
por: Abenavoli, Ludovico, et al.
Publicado: (2023)

Comment on a recent article titled “Circulating level of fatty acid‐binding protein 4 is an independent predictor of metabolic dysfunction‐associated fatty liver disease in middle‐aged and elderly individuals”
por: Naharci, Mehmet Ilkin, et al.
Publicado: (2022)

Reply to the comments of Naharci et al. on “Circulating level of fatty acid‐binding protein 4 is an independent predictor of metabolic dysfunction‐associated fatty liver disease in middle‐aged and elderly individuals”
por: Tanaka, Marenao, et al.
Publicado: (2022)

Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
por: Alharthi, Jawaher, et al.
Publicado: (2022)

Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
por: Lee, Jung Il
Publicado: (2022)

Therapeutic developments in metabolic dysfunction-associated fatty liver disease
por: Shi, Yiwen, et al.
Publicado: (2022)

Cardiometabolic characterization in metabolic dysfunction–associated fatty liver disease
por: Perdomo, Carolina M., et al.
Publicado: (2022)

Low–Normal Thyroid Function Is Not Associated with Either Non-Alcoholic Fatty Liver Disease or with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Zuarth-Vázquez, Julia, et al.
Publicado: (2023)

The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease
por: Martín-Mateos, Rosa, et al.
Publicado: (2021)

Fatty liver with metabolic disorder, such as metabolic dysfunction‐associated fatty liver disease, indicates high risk for developing diabetes mellitus
por: Miyake, Teruki, et al.
Publicado: (2022)

The Importance of Visceral Adipose Tissue Detected by Imaging Methods to Assess Nonalcoholic Fatty Liver Disease Properly
por: Ozcelik, Fatih, et al.
Publicado: (2021)

No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease
por: Biquard, Louise, et al.
Publicado: (2020)

Personalised medicine: are we ready?
por: Louis, Renaud, et al.
Publicado: (2017)

Perspective: Towards Personalised Metabolic Coaching in Cancer
por: Van Soom *, T, et al.
Publicado: (2018)

Personalised cancer follow-up: risk stratification, needs assessment or both?
por: Filleron, T, et al.
Publicado: (2012)

Aerobic Exercise in the Management of Metabolic Dysfunction Associated Fatty Liver Disease
por: Machado, Mariana Verdelho
Publicado: (2021)

Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis
por: Wang, Xiaolin, et al.
Publicado: (2022)

Quality of Life in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease
por: Hwang, Tae-In, et al.
Publicado: (2021)

Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease
por: Lin, Huapeng, et al.
Publicado: (2021)

Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
por: Subramanian, Pallavi, et al.
Publicado: (2022)

Implications of metabolic dysfunction associated fatty liver disease in COVID-19
por: Chakraborty, Raja, et al.
Publicado: (2023)

Non-invasive assessment of metabolic dysfunction–associated fatty liver disease
por: Chandra Kumar, C. Vikneshwaran, et al.
Publicado: (2022)

Metabolic dysfunction-associated fatty liver disease in people living with HIV
por: Michel, Maurice, et al.
Publicado: (2023)

Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
por: Song, Byeong Geun, et al.
Publicado: (2023)

Mediterranean diet affects the metabolic outcome of metabolic dysfunction-associated fatty liver disease
por: Xiao, Yuji, et al.
Publicado: (2023)

Metabolically Healthy Obesity (MHO)—New Research Directions for Personalised Medicine in Cardiovascular Prevention
por: Nilsson, Peter M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mf40bsoiulseifg0vpp81oc2jk